Cancer drug discovery breakthroughs: research that’s changing lives

Dr. Adriana Kahn, Assistant Professor of Medicine (Medical Oncology)

Dr Adriana Kahn cares for patients as part of the Center for Breast Cancer and the Drug Development Department at Yale Cancer Center. She completed a fellowship in Medical Oncology at the Yale School of Medicine and completed residency at the University of Connecticut. Prior to coming to the United States, she completed a fellowship in Breast Cancer in Canada. She completed residency and medical oncology fellowship at the Universidade de Sao Paulo, Brazil, receiving her medical degree from the Universidade Federal da Bahia, Brazil.

Stephen Neidle – Emeritus Professor of Chemical Biology and CRUK Professorial Fellow, UCL School of Pharmacy

Professor Stephen Neidle is a chemistry graduate of Imperial College (DSc, PhD, ARCS), where he also undertook research on the structures of a number of complex natural products and antibiotics. After a period as an ICI Fellow of the University of London with MB Hursthouse, he joined the Biophysics Department at King’s College London, which initiated his interest in nucleic acid structural studies. He was one of the first Cancer Research Campaign Career Development Awardees, and was a Life Fellow and Professorial Fellow of Cancer Research UK 1986-2012. His work has been recognized by a number of awards, including the Sosnovsky and Aventis Prizes for work on the medicinal chemistry of cancer, the Interdisciplinary and Medicinal Chemistry Award of the Royal Society of Chemistry, the Paul Ehrlich, Kelland and Guggenheim Lectureships, and a visiting Professorship at the University of Rome.

Dr. Juliana Maynard – Head of Translational Imaging at Medicines Discovery Catapult and Director of Operations and Engagement for the National PET Imaging Platform

Dr Juliana Maynard is an expert imaging scientist with over 20 years’ experience in translational imaging and therapeutic precision medicine. Juliana developed, established, and is now the Director of Operations and Engagement at the National PET Imaging Platform, where she is accountable for strategically building and growing collaborative opportunities to use the platform and its cutting-edge total-body PET imaging technology. She is also Head of Translational Imaging at Medicines Discovery Catapult.

Dr. Steve Shnyder is an Associate Professor in Tumour Biology at the Institute of Cancer Therapeutics, University of Bradford.

Steve earned his PhD from University College London and went on to hold postdoctoral positions at Cardiff University, the University of Bath, and the University of Otago, where he conducted research in osteosarcoma biology, homeobox gene regulation and expression, and the characterisation of a novel reticuloplasmin, respectively. He later worked at Gendel Ltd, a start-up biotechnology company in Coleraine, focusing on novel drug delivery technologies.

Dr Kristi Savill, PhD – Director, Scientific Engagement – Precision Oncology

Dr. Savill is a leader in precision oncology and real-world evidence research and has over two decades of research experience. She is currently serving as Director, Scientific Engagement – Precision Oncology at Flatiron Health and is passionate about delivering strong scientific evidence to support clinical, development, and regulatory decision-making and improve and extend the lives of patients. Dr. Savill’s prior roles include Scientific Director in the Real World Evidence & Insights team of Cardinal Health and Scientific Manager in the Oncology Biomarker Development division at Genentech. She holds a PhD in Biochemistry and completed a four-year post-doctoral training program in the department of Translational Oncology at Genentech

Steve Wedge – Chief Scientific Officer, Cancer Research Horizons and Professor of Stratified Cancer Medicine Discovery, Newcastle University

Steve is a cancer pharmacologist who has specialised in oncology drug discovery and development for over 35 years. He is a contributor to the discovery of 12 candidate oncology drugs, 8 of which have been evaluated clinically, including the discovery of Caprelsa^®, the first targeted therapy for the treatment of advanced medullary thyroid cancer. More recently, he was part of the joint Astex-Newcastle project team that identified the novel MDM2-p53 antagonist, ASTX295. He has experience across all drug discovery phases; from target selection and validation, lead identification and optimisation, through to translational science and early clinical development. Steve is Chief Scientific Officer for Cancer Research Horizons Therapeutic Innovation, CRUK’s drug discovery organisation.

Is the webinar free?
Yes – there is no charge to watch the webinar, either live or on-demand.

I’m busy. Can I watch it later?
The webinar will become available to watch on-demand shortly after the live webinar takes place.

How long will the webinar be?
This webinar will last for up to one hour.

What do I need to watch this webinar?
All you need is a computer with an internet connection. Be sure to use headphones if in an office environment.